BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
21 hedge funds and large institutions have $10.7M invested in BRAINSTORM CELL THERAPUTC in 2015 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 2 closing their positions.
2,095% more capital invested
Capital invested by funds: $488K → $10.7M (+$10.2M)
500% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 2
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
91% more funds holding
Funds holding: 11 → 21 (+10)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$5.94M |
| 2 |
PA
Perceptive Advisors
New York
|
+$1.69M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.36M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$186K |
| 5 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$174K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
-$3K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
-$1.07K |
BCLI Hedge Fund Activity: Q1 2015 in Review
21 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q1 2015, worth a combined $10.7M — up 2,095% from $488K a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new BCLI positions and 2 closed out — a net gain of 10 holders — while 5 added to existing stakes and 1 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $5.94M. The largest seller was PNC Financial Services Group, exiting entirely with an estimated $3K sold.
- 21 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q1 2015, up from 11 in Q4 2014.
- Funds reported $10.7M of BRAINSTORM CELL THERAPUTC stock for Q1 2015, up 2,095% quarter-over-quarter.
- 12 funds opened new BRAINSTORM CELL THERAPUTC positions in Q1 2015 and 2 closed out, a net change of +10 holders.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q1 2015 was Sabby Management, an estimated $5.94M added.
- The largest BRAINSTORM CELL THERAPUTC seller in Q1 2015 was PNC Financial Services Group, an estimated $3K sold.
Based on aggregated 13F filings for Q1 2015.